Nov 3, 2025, 08:52 AM by

Lonza has announced that it has signed an agreement to acquire Redberry.

Oct 30, 2025, 08:36 AM by

Oct 30, 2025, 08:36 AM by

EazeBio has announced a strategic partnership with the University of California, Santa Cruz to advance and commercialize a groundbreaking instrument-free diagnostic platform.

Oct 30, 2025, 01:01 AM by User Not Found

Bio-IT World | NVIDIA CEO Jensen Huang used NVIDIA’s GTC 2025 keynote to share his vision for the convergence of quantum computing and artificial intelligence, while revealing staggering demand for the company’s next-generation Grace Blackwell architecture that signals a fundamental shift in how the world computes.

Oct 29, 2025, 05:36 AM by User Not Found

Bio-IT World | SandboxAQ releases AQCat25-EV2, a new quantitative AI model trained on the AQCat25 dataset; Illumina launches BioInsight, a new business within Illumina developed to meet industry demand for deeper biologic insights; Thermo Fisher Scientific introduces the Applied Biosystems SwiftArrayStudio Microarray Analyzer; and more.

Oct 28, 2025, 09:08 AM by

Spaarne Gasthuis, a top clinical teaching hospital serving part of the Greater Amsterdam region, is fully digitizing its pathology practice with Concentriq® AP-Dx* from Proscia®. With this software platform, the hospital will empower its pathologists to play an even more significant role in guiding personalized treatment decisions for hundreds of thousands of patients each year.

Oct 28, 2025, 01:01 AM by User Not Found

Bio-IT World | Kailera Therapeutics advances injectable dual GLP-1/GIP receptor agonist; Tubulis develops antibody-drug conjugate for ovarian cancer and lung adenocarcinomas; Trogenix advances their pipeline of potentially curative cancer therapies across multiple aggressive solid tumors into the clinic; and more.

Oct 28, 2025, 01:00 AM by User Not Found

Bio-IT World | Kailera Therapeutics advances injectable dual GLP-1/GIP receptor agonist; Tubulis develops antibody-drug conjugate for ovarian cancer and lung adenocarcinomas; Trogenix advances their pipeline of potentially curative cancer therapies across multiple aggressive solid tumors into the clinic; and more.

Oct 24, 2025, 09:10 AM by

Elixion Biotech has emerged from stealth with a breakthrough that could reshape early-stage drug discovery. In just eleven months, and without external funding, the Zurich-based therapeutics company has validated its quantum physics-informed R&D process, confirming its ability to accurately predict and identify novel drug targets. The milestone positions Elixion to advance its precision-oncology pipeline and opens the door to seed-stage investment.

Oct 24, 2025, 09:10 AM by

Leading Global Cancer Center to Integrate Triomics AI Platform to Improve Clinical Trial Screening

Oct 24, 2025, 09:10 AM by

Oct 23, 2025, 08:15 AM by

Oct 23, 2025, 08:15 AM by

Oct 23, 2025, 08:15 AM by

Recognized for Global Precision Health Informatics Industry Excellence in Best Practices

Oct 23, 2025, 08:15 AM by

Ansa Biotechnologies announced the full commercial launch of its 50kb Clonal DNA product – the longest sequence-perfect synthetic DNA commercially available.

Oct 23, 2025, 08:15 AM by

Oximio, a global leader in supply chain solutions for the clinical research industry, is delighted to welcome Bay Area Research Logistics (BARL), Canada to the Oximio family with the agreement signed on 17th October 2025, a strategic move that strengthens Oximio’s global footprint and enhances its capabilities across the globe.

Oct 23, 2025, 08:15 AM by

Oct 23, 2025, 01:01 AM by User Not Found

Bio-IT World | Researchers have developed a generative transformer model capable of forecasting an individual’s risk of developing over 1,200 diseases a decade in advance. The model, called Delphi-2M, was validated using data on about 2 million individuals from Denmark’s National Patient Registry without retraining.

Oct 22, 2025, 07:10 AM by

Sionna Therapeutics has initiated its Phase 2a PreciSION CF trial evaluating SION-719, the first NBD1 stabilizer, in combination with Trikafta in people with cystic fibrosis. The study marks the first time an NBD1 stabilizer has been tested alongside the current standard of care, representing a key step toward validating NBD1 as a novel, synergistic mechanism to further improve CFTR function.

Oct 22, 2025, 07:10 AM by